4+ day, 21+ hour ago   (358+ words) Allen Khudaverdyan, MD, NYU Grossman School of Medicine, New York, New York, discusses results from a large retrospective analysis evaluating the association between concurrent statin use and overall survival in patients with head and neck squamous cell carcinoma treated with…...

5+ day, 22+ hour ago   (652+ words) Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, New York, discusses how findings from the phase 3 HERIZON-GEA-01 trial are reshaping first-line treatment of HER2-positive gastroesophageal adenocarcinoma following the approval of zanidatamab plus chemotherapy, with or without tislelizumab. He…...

6+ day, 1+ hour ago   (273+ words) Based on results from the phase 3 SERENA-6 trial, the US Food and Drug Administration (FDA) granted accelerated approval to camizestrant (Etcamah; AstraZeneca) in combination with a CDK4/6 inhibitor for patients with HR-positive, HER2-negative locally advanced or metastatic breast cancer following detection…...

2+ week, 3+ day ago   (839+ words) Andrew Hahn, MD, MD Anderson Cancer Center, Houston, Texas, presents a case of de novo metastatic prostate cancer to illustrate how comprehensive molecular profiling can inform upfront treatment selection. Hi, my name is Andy Hahn, I'm an assistant professor of…...

2+ week, 6+ day ago   (192+ words) The approval of zanidatamab plus tislelizumab and chemotherapy applies to patients with HER2 IHC 3+ or IHC 2+/ISH+ tumors, while zanidatamab plus chemotherapy without tislelizumab is approved for patients with HER2 IHC 3+ disease. HER2 positivity must be confirmed using an FDA-approved test. PFS was…...